Docket Number: 037003-0313914 PATENT APPLICATION

#45

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

HARIHARAN et al.

Application No.: 10/530,951

Filed: December 6, 2004

Group Art Unit: To be determined

Examiner: To be determined

Confirmation No.: To be determined

For: GENES OVEREXPRESSED BY CANCER AND THEIR USE IN DEVELOPING NOVEL THERAPEUTICS

June 16, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, the applicants hereby bring to the examiner's attention references that may be material to the examination of the above-identified application. In compliance with 37 C.F.R. §1.97 and §1.98, the applicants enclose herein a completed Form PTO-1449 listing the possibly pertinent references. A copy of each required reference according to 37 C.F.R. §1.98 (a)(2)(i) is also enclosed.

It is respectively requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "Reference Cited" on any patent issued therefrom.

This Information Disclosure Statement is submitted prior to receipt of a first office action on the merit. Therefore, under 37 C.F.R. §1.97(b), this Information Disclosure Statement shall be considered by the Patent Office. Accordingly, no fee as set forth in 37 C.F.R. §1.17(p) is due.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

PILLSBURY WINTHROP SHAW PITTMAN LLP
P.O. Box 10500
McLean, VA 22102
Telephone: (703) 905-2000
Facsimile: (703) 905-2500

TAC/PAJ/YMD

FORM PTO-1449 (modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



Atty. Ref. No.	Client Ref. No.
037003-0313914	2001-30-0178QUS

Applicant: HARIHARAN et al.

Appln. No.: 10/530,951

Filing Date: December 6, 2004

Date: JUNE 16, 2005 Page 1 of 3

Examiner: Unassigned | Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
	AR	5,547,856	08/1996	Godowski
	BR	5,585,103	12/1996	Raychaudhuri
	CR	5,645,995	07/1997	Kieback
	DR	5,661,126	08/1997	Donahoe
	ER	5,683,885	11/1997	Kieback
	FR	5,695,770	12/1997	Raychaudhuri
	GR	5,709,860	01/1998	Raychaudhuri
	HR	5,725,856	03/1998	Hudziak
	IR	5,729,954	03/1998	Lines
	JR	5,770,195	06/1998	Hudziak
	KR	5,772,997	06/1998	Hudziak
	LR	5,814,315	09/1998	Hung
	MR	5,891,857	04/1999	Holt
	NR	5,968,748	10/1999	Bennett
	OR	5,972,675	10/1999	Beckmann
	PR	6,001,583	12/1999	Margolis
	QR	6,007,997	12/1999	Diep
	RR	6,037,134	03/2000	Margolis
	SR	6,040,290	03/2000	Lippman
	TR	6,045,997	04/2000	Futreal

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	UR	WO01/18046 A	03/2001	PCT	Xu		
	VR	WO01/57194 A	08/2001	PCT	Madison		
	WR	WO01/92581 A2	12/2001	PCT	Algate		
	XR	WO03/59256 A	07/2003	PCT	McLachlan		
	YR	WO03/104429 A2	12/2003	PCT	Hariharan		

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	ZR	Bandoh K et al., "Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid," *J. Biol. Chem.*, 1999, 274: 27776-85.
	AAR	Barnea E et al., "Analysis of endogenous peptides bound by soluble MGC class I molecules: a novel approach for identifying tumor-specific antigens," *Eur. J. Immunol.*, 2002, 32: 213-22.
	BBR	Clark HF et al., "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment," *Genome Res.*, 2003, 13: 2265-70.
	CCR	Crosbie RH et al., "Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions," *Human Molecular Genetics*, 2000, 9: 2019-27.

	DDR	Crosbie RH et al., "Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex," *J. Biol. Chem.*, 1997, 272: 31221-4.
	EER	Ericsson TA et al., "Identification of receptors for pig endogenous retrovirus," *Proc. Natl. Acad. Sci. USA*, 2003, 100: 6759-64.
	FFR	Fitzgerald LR et al., "Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid," *Biochem. Biophys. Res. Commun.*, 2000, 273: 805-10.
	GGR	Fujita T et al., "Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer," *Cancer Lett.*, 2003, 192:161-9.
	HHR	Hama K et al., "Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors," *FEBS Lett.*, 2002, 523:187-92.
	IIR	Heighway J et al., "Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG," *Genomics*, 1996, 35: 207-14.
	JJR	Hillier LD et al., "Generation and analysis of 280,000 human expressed sequence tags," *Genome Res.*, 1996, 6: 807-28.
	KKR	Im DS et al., "Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate," *Mol. Pharmacol.*, 2000, 57: 753-9.
	LLR	Ishikawa K et al., "Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro," *DNA Res.*, 1997, 4: 307-13.
	MMR	Kanai Y et al., "Identification of two Sox17 messenger RNA isoforms, with and without the high mobility group box region, and their differential expression in mouse spermatogenesis," *J. Cell Biol.*, 1996, 133: 667-81.
	NNR	Kanai-Azuma M et al., "Depletion of definitive gut endoderm in Sox17-null mutant mice," *Development*, 2002, 129: 2367-79.
	OOR	Medl M et al., "TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer," *Br. J. Cancer*, 1995, 71: 1051-4.
	PPR	Nagase T et al., "Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro," *DNA Res.*, 2000, 7: 65-73.
	QQR	Nagase T et al., "Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1," *DNA Res.*, 1995, 2: 37-43.
	RRR	O'Brien KF et al., "Analysis of human sarcospan as a candidate gene for CFEOM1," *BMC Genet.*, 2001, 2: 3.
	SSR	Ota T et al., "Complete sequencing and characterization of 21,243 full-length human cDNAs," *Nat. Genet.*, 2004, 36: 40-5.
	TTR	Scambia G et al., "Significance of epidermal growth factor receptor in advanced ovarian cancer," *J. Clin. Oncol.*, 1992, 10: 529-35.
	UUR	Scheffer G et al., "Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells," *Brit. J. Cancer.*, 2002, 86: 1943-50.
	VVR	Scott AF et al., "Characterization of a gene coamplified with Ki-ras in Y1 murine adrenal carcinoma cells that codes for a putative membrane protein," *Genomics*, 1994, 20: 227-30.
	WWR	Wallrapp C et al., "A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer," *Cancer Res.*, 2000, 60: 2602-6.
	XXR	Wu K et al., "[Cloning and expression analyses of down-regulated cDNA C6-2A in human esophageal cancer]," *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*, 1999, 16: 325-7. (Abstract Only).
	YYR	GenBank Accession No. AI683094
	ZZR	GenBank Accession No. AI821669
	AAAR	GenBank Accession No. AI866319
	BBBR	GenBank Accession No. NM_011441
	CCCR	GenBank Accession No. AI498957
	DDDR	GenBank Accession No. W84863
	EEER	GenBank Accession No. AI923224

	FFFR	GenBank Accession No. AI537678
	GGGR	GenBank Accession No. AK024365
	HHHR	GenBank Accession No. AI092936
	IIIR	GenBank Accession No. AI801043
	JJJR	GenBank Accession No. NM_024531
	KKKR	GenBank Accession No. AI742002
	LLLR	GenBank Accession No. AI868025
	MMMR	GenBank Accession No. AI219073
	NNNR	GenBank Accession No. AI688913
	OOOR	GenBank Accession No. AF282167
	PPPR	GenBank Accession No. AI741736
	QQQR	GenBank Accession No. AI539017
	RRRR	GenBank Accession No. AB037805
	SSSR	GenBank Accession No. AI871120
	TTTR	GenBank Accession No. AI924459
	UUUR	GenBank Accession No. AA830718
	VVVR	GenBank Accession No. AB007876
	WWWR	GenBank Accession No. KIAA0416
	XXXR	GenBank Accession No. AK056644
	YYYR	GenBank Accession No. AB007876
	ZZZR	GenBank Accession No. AK056644
	AAAAR	GenBank Accession No. NM_024993
	BBBBR	GenBank Accession No. AB060846
	CCCCR	GenBank Accession No. BAA24846
	DDDDR	GenBank Accession No. BAB71240
	EEEER	GenBank Accession No. NP_079269
	FFFFR	GenBank Accession No. BAB46868
	GGGGR	GenBank Accession No. AW161290
	HHHHR	GenBank Accession No. AW157718
	IIIIR	GenBank Accession No. BE551640
	JJJJR	GenBank Accession No. AW874138
	KKKKR	GenBank Accession No. AA977181
	LLLLR	GenBank Accession No. AA767317
	MMMMR	GenBank Accession No. AI143233
	NNNNR	GenBank Accession No. NP_055862
	OOOOR	GenBank Accession No. NM_016425
	PPPPR	GenBank Accession No. CAC60389
	QQQQR	GenBank Accession No. AW044646
	RRRRR	GenBank Accession No. NM_005086.3
	SSSSR	GenBank Accession No. NM_012152
	TTTTR	GenBank Accession No. NP_036284

Examiner	Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.